Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia.
about
Toxin-based therapeutic approachesCD45 phosphatase is crucial for human and murine acute myeloid leukemia maintenance through its localization in lipid raftsAcute myeloid leukemia-targeted toxin activates both apoptotic and necroptotic death mechanismsActivity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients.GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia.Potent antitumor activity of a urokinase-activated engineered anthrax toxin.Resimmune, an anti-CD3ε recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma.Diphtheria toxin-epidermal growth factor fusion protein DAB389EGF for the treatment of bladder cancerIssues related to targeted delivery of proteins and peptides.In vivo characterization of fusion protein comprising of A1 subunit of Shiga toxin and human GM-CSF: Assessment of its immunogenicity and toxicityRecombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignanciesOptimization of the Expression of DT386-BR2 Fusion Protein in Escherichia coli using Response Surface MethodologyDevelopment of a nonintegrating Rev-dependent lentiviral vector carrying diphtheria toxin A chain and human TRAF6 to target HIV reservoirs.Recombinant hybrid protein, Shiga toxin and granulocyte macrophage colony stimulating factor effectively induce apoptosis of colon cancer cells.Clinical targeting recombinant immunotoxins for cancer therapyDiphtheria toxin fused to variant human interleukin-3 induces cytotoxicity of blasts from patients with acute myeloid leukemia according to the level of interleukin-3 receptor expression.Exploring Cytotoxic mRNAs as a Novel Class of Anti-cancer Biotherapeutics.
P2860
Q27013664-57AD9F89-432D-406E-BD5A-18E9823A134CQ28278205-5771221C-227D-43D1-B915-7C91C0E4BEEBQ33392660-0D9C4FD5-7832-49F2-A56A-6E26C11B64D5Q33415505-78E54049-71BC-4486-B40A-84ECADDB2062Q34342071-2A158979-1440-481A-8982-2A0D25F0F735Q34470439-0A0305AA-581B-4353-A8D0-8BAD608AE08DQ35669880-B23F1926-FB87-4E29-89C8-23B092DDE2BCQ36511054-4DAD82C0-5E95-4786-96C9-85A3C6A6AD67Q36616311-CC9C0013-FB21-46E9-95BE-2C5696DEA64FQ36784613-11A74B33-FBA2-468A-A8E9-80A11CF35AFCQ37165245-26DC7F0D-36B9-4A53-86AD-3462F497CBF5Q38738810-FCEC6145-F3F0-43F0-8765-E029E6EDBD6DQ39712011-D0C3E9DC-5D65-4B1E-B070-07DF85E09942Q40281292-8B89A740-E199-4E88-A7F1-D72733139064Q41149227-C0C76BED-FE1D-4780-9C37-3957CE4735CDQ41897967-4557C4B7-C7A9-4E0A-8D5C-BCACE6292B2DQ52568128-6905C21C-76C5-43C1-BF4A-2A05264E1DF2
P2860
Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Phase I trial of a novel dipht ...... lapsed acute myeloid leukemia.
@en
Phase I trial of a novel dipht ...... mulating factor fusion protein
@nl
type
label
Phase I trial of a novel dipht ...... lapsed acute myeloid leukemia.
@en
Phase I trial of a novel dipht ...... mulating factor fusion protein
@nl
prefLabel
Phase I trial of a novel dipht ...... lapsed acute myeloid leukemia.
@en
Phase I trial of a novel dipht ...... mulating factor fusion protein
@nl
P2093
P1476
Phase I trial of a novel dipht ...... elapsed acute myeloid leukemia
@en
P2093
Bayard L Powell
L Douglas Case
Philip D Hall
Robert J Kreitman
P304
P407
P577
2002-05-01T00:00:00Z